within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AX16_Inclisiran;

model Inclisiran
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4e-05,
    adminDuration = 600,
    adminMass = 284 / 1000000,
    adminCount = 1,
    Vd = 0.5,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.525,
    k12 = 3.916666666666667e-06,
    k21 = 3.916666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Inclisiran</td></tr><tr><td>ATC code:</td><td>C10AX16</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>284</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>500</td><td>L</td></tr>
    <tr><td>clearance:</td><td>144</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Inclisiran is a small interfering RNA (siRNA) drug that targets and degrades PCSK9 mRNA in the liver, leading to lower levels of LDL cholesterol. It is used in the treatment of hypercholesterolemia and is approved for use in adults with elevated LDL-C who are at high risk for cardiovascular events.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult subjects with hypercholesterolemia or mixed dyslipidemia after a single subcutaneous dose.</p><h4>References</h4><ol><li><p>Yamashita, S, et al., &amp; Kajinami, K (2024). Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15. <i>Journal of atherosclerosis and thrombosis</i> 31(6) 876–903. DOI:<a href=\"https://doi.org/10.5551/jat.64454\">10.5551/jat.64454</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38220186/\">https://pubmed.ncbi.nlm.nih.gov/38220186</a></p></li><li><p>Luo, Z, et al., &amp; He, Y (2023). The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. <i>Journal of clinical lipidology</i> 17(3) 392–400. DOI:<a href=\"https://doi.org/10.1016/j.jacl.2023.04.010\">10.1016/j.jacl.2023.04.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37164838/\">https://pubmed.ncbi.nlm.nih.gov/37164838</a></p></li><li><p>Jeon, JY, et al., &amp; Mitra, A (2022). Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview. <i>Pharmaceutical research</i> 39(8) 1749–1759. DOI:<a href=\"https://doi.org/10.1007/s11095-022-03333-8\">10.1007/s11095-022-03333-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35819583/\">https://pubmed.ncbi.nlm.nih.gov/35819583</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C10AX16 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Inclisiran;
